“mpm-capital” Archives

Entry Author Date Location
Seeking Tau: BMS Buys iPierian and Brain-Disease Program for $175M 04/29/14 San Francisco
Syndax Plots $69M IPO For Cancer Drug’s Stretch Run 03/27/14 Boston
Proteon, Looking Past Ill-Fated Novartis Deal, Goes it Alone 03/18/14 Boston
Revamped Radius Health Looks to Cash In With $86M IPO 02/27/14 Boston
East Coast Biotech Roundup: HART, CoStim, Forest/Actavis, & More 02/21/14 Boston
Immuno-Oncology Fever Rages as Novartis Snaps Up CoStim 02/18/14 Boston
Radius Health Churns Through 3 CEOs, as Osteoporosis Drug Delayed 12/20/13 Boston
Trivascular Obtains $40,000,000 Series E Funding Round 11/18/13 San Francisco
East Coast Biotech Roundup: Pronutria, Alzheon, Nextcode, & More 10/25/13 Boston
Sideris Pharmaceuticals Receives $32,000,000 Series A Funding 10/23/13 Boston
Mitokyne Garners $45,000,000 Series A Financing Round 10/21/13 Boston
East Coast Life Sciences Roundup: Verdine, Ariad, Karyopharm, & More 10/11/13 Boston
iPierian Receives $30,000,000 New Funding Round 09/04/13 San Francisco
True North Therapeutics Garners Series A Funding 09/04/13 San Francisco
East Coast Life Sciences Roundup: Syndax, Enteris, Invivo, & More 08/30/13 Boston
Syndax Pockets $26.6M For Final Stage Push With Cancer Drug 08/27/13 Boston
Syndax Pharmaceuticals Lands $26,600,000 Series B Financing 08/27/13 Boston
VLST, After Nine Years and $50M, Sells Assets and Winds Down 08/07/13 Seattle
San Diego’s Conatus Pharmaceuticals Sets Price Range for IPO Shares 07/09/13 San Diego
Epizyme Soars 50 Percent in IPO Debut 05/31/13 Boston
Epizyme Prices IPO at $15 Per Share, Begins Trading Friday 05/30/13 Boston
Radius Health CEO: Skin Patch Data is the Value Driver 05/13/13 Boston
East Coast Life Sciences Roundup: Bind, Gen9, Radius, Cydan 04/26/13 Boston
Radius Health Receives $43,000,000 New Round 04/26/13 Boston
Radius Health, Still Private, Raises Another $43M 04/25/13 Boston
Theraclone Secures $14M to Push Antibody Drug Programs 03/25/13 Seattle
Theraclone Sciences Garners $14,000,000 Series B Financing 03/25/13 Seattle
Theraclone Sciences Receives $14,000,000 Series B Funding Round 03/25/13 Seattle
Nevro Obtains $48,000,000 Series C Funding Round 03/07/13 San Francisco
California Stem Cell Agency Shifts Focus to Clinical Treatments 01/31/13 San Francisco
Page 2 of 8 « previous page · next page »